Designing drug-free biodegradable nanoparticles to modulate inflammatory monocytes and neutrophils for ameliorating inflammation

Inflammation associated with autoimmune diseases and chronic injury is an initiating event that leads to tissue degeneration and dysfunction. Inflammatory monocytes and neutrophils systemically circulate and enter inflamed tissue, and pharmaceutical based targeting of these cells has not substantial...

Full description

Saved in:
Bibliographic Details
Published inJournal of controlled release Vol. 300; pp. 185 - 196
Main Authors Saito, Eiji, Kuo, Robert, Pearson, Ryan M., Gohel, Nishant, Cheung, Brandon, King, Nicholas J.C., Miller, Stephen D., Shea, Lonnie D.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 28.04.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Inflammation associated with autoimmune diseases and chronic injury is an initiating event that leads to tissue degeneration and dysfunction. Inflammatory monocytes and neutrophils systemically circulate and enter inflamed tissue, and pharmaceutical based targeting of these cells has not substantially improved outcomes and has had side effects. Herein, we investigated the design of drug-free biodegradable nanoparticles, notably without any active pharmaceutical ingredient or targeting ligand, that target circulating inflammatory monocytes and neutrophils in the vasculature to inhibit them from migrating into inflamed tissue. Nanoparticles were formed from 50:50 poly(DL-lactide-co-glycolide) (PLG) with two molecular weights (Low, High) and poly(DL-lactide) (PLA) (termed PLG-L, PLG-H, and PDLA, respectively) and were analyzed for their association with monocytes and neutrophils and their impact on disease course along with immune cell trafficking. For particles injected intravenously for 6 consecutive days to mice with experimental autoimmune encephalomyelitis (EAE), PLG-H particles had significantly lower EAE clinical scores than PBS control, while PLG-L and PDLA particles had modest or negligible effect on EAE onset. In vivo and in vitro data suggests that PLG-H particles had high association with immune cells, with preferential association with blood neutrophils relative to other particles. PLG-H particles restrained immune cells from the central nervous system (CNS), with increased accumulation in the spleen, which was not observed for mice receiving PDLA or control treatments. These results demonstrate that the particle composition influences the association with inflammatory monocytes and neutrophils in the vasculature, with the potential to redirect trafficking and ameliorate inflammation. [Display omitted] •Drug-free biodegradable particles modulate inflammation, though the design matters.•High molecular weight polymeric particles ameliorated EAE.•Particle positive cells were observed in the spleen and not the CNS for EAE.•Particles effective at attenuating EAE preferentially associated with neutrophils.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2019.02.025